# Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

> **NCT02163317** · NA · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer
- Stage I Prostate Cancer
- Stage IIA Prostate Cancer
- Stage IIB Prostate Cancer

## Interventions

- **RADIATION:** stereotactic radiosurgery
- **DEVICE:** magnetic resonance imaging
- **OTHER:** quality-of-life assessment
- **PROCEDURE:** Serum Prostate Antigen Test
- **PROCEDURE:** Digital Rectal Exam
- **BEHAVIORAL:** Expanded Prostate Cancer Index Composite

## Key facts

- **NCT ID:** NCT02163317
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-16
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-07-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02163317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02163317, "Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02163317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*